50 results on '"Takahashi, Shunji"'
Search Results
2. O19-4 Outcomes in Japanese patients with TMB-high and non-TMB-high solid tumors treated with pembrolizumab: KEYNOTE-158
3. PS4-2 Analysis of the COLLECT Study - Efficacy and safety of lenvatinib in differentiated thyroid cancer
4. O1-7-5 - Incidence and risk factors of interstitial lung disease (ILD) of head and neck cancer patients treated with Cetuximab
5. P1-293 - Eight patients with mucosal malignant melanoma treated by nivolumab: a retrospective analysis in a single institution
6. P20-2 Comparison of triweekly cisplatin regimens in adjuvant chemoradiotherapy for locally advanced head and neck cancer
7. P46-2 A case of cancer-associated dermatomyositis diagnosed after curative therapy for esophageal and oropharyngeal cancers
8. MO33-7 Preparedness for COVID-19 pandemic and impact on medical oncology for breast cancer
9. MO9-5 Clinical implementation of cancer genomic medicine using gene profiling test under national health insurance in Japan
10. P48-8 A case of primary lung cancer that led to the diagnosis of SMARCA4-deficient thoracic sarcoid tumor by oncogene panel testing
11. Efficacy and safety of lenvatinib in 124 Japanese patients with anaplastic thyroid cancer
12. The clinical efficacy of eribulin to soft tissue sarcoma patients: differences in histological subtypes
13. Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer
14. Liquid biopsy for detection of actionable mutation in various cancer patients
15. Japanese Subgroup Analysis of KEYNOTE-048: Ph3 Study of 1L Pembrolizumab for R/M Head and Neck Squamous Cell Carcinoma
16. Preliminary results from fight-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies
17. Efficacy and safety of nivolumab in patients with uterine cervical cancer, uterine corpus cancer, or soft-tissue sarcoma
18. Eight patients with mucosal malignant melanoma treated by nivolumab: a retrospective analysis in a single institution
19. Treatment strategy for advanced soft tissue sarcoma
20. Incidence and risk factors of interstitial lung disease (ILD) of head and neck cancer patients treated with Cetuximab
21. Weekly Paclitaxel plus Cetuximab in the primary treatment of metastatic/recurrent squamous cell cancer of head and neck
22. Involvement of medical oncologists in the treatment of urological cancer
23. Vandetanib for thyroid cancer
24. Clinical trials of trabectedin for soft tissue sarcoma
25. Phase Ia/Ib study of taselisib in Japanese patients with solid tumors or hormone receptor positive breast cancer
26. P1-185 - Liquid biopsy for detection of actionable mutation in various cancer patients
27. P1-156 - Preliminary results from fight-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies
28. P1-126 - The clinical efficacy of eribulin to soft tissue sarcoma patients: differences in histological subtypes
29. O1-8-4 [Encore] - Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer
30. O1-2-3 - Japanese Subgroup Analysis of KEYNOTE-048: Ph3 Study of 1L Pembrolizumab for R/M Head and Neck Squamous Cell Carcinoma
31. MO3-3-1 - Efficacy and safety of lenvatinib in 124 Japanese patients with anaplastic thyroid cancer
32. New development on bone metastasis treatment
33. Chemotherapy for castration resistant prostate cancer: new perspectives
34. Management and treatment of soft tissue sarcoma patients by medical oncologists in multidisciplinary center
35. Treatment results of trabectedin (T) in patients (pts) with myxoid-round cell liposarcoma (MRCL)
36. O3-2-2 - Efficacy and safety of nivolumab in patients with uterine cervical cancer, uterine corpus cancer, or soft-tissue sarcoma
37. SY9-2 - Treatment strategy for advanced soft tissue sarcoma
38. The Pattern of Tumor Shrinkage is Associated with Prognosis in Luminal Breast Cancer During Neoadjuvant Chemotherapy
39. Risk Factors of Prolonged Duration of Gastrosoma Placement in Locally Advanced Head and Neck Cancer Patients with Ccrt
40. Molecular Targeting Therapy for Thyroid Cancer: Problems in Clinical Practice
41. Opioid Requirements to Control Mucositis During Chemoradiotherapy in Head and Neck Cancer: Cisplatin Vs. Cetuximab
42. O3-11-1 - Weekly Paclitaxel plus Cetuximab in the primary treatment of metastatic/recurrent squamous cell cancer of head and neck
43. SY-14-2 - Involvement of medical oncologists in the treatment of urological cancer
44. ISY-13-4 - Clinical trials of trabectedin for soft tissue sarcoma
45. ISY-6-1 - Vandetanib for thyroid cancer
46. ISY-4-4 - Phase Ia/Ib study of taselisib in Japanese patients with solid tumors or hormone receptor positive breast cancer
47. P2-1-2 - Opioid Requirements to Control Mucositis During Chemoradiotherapy in Head and Neck Cancer: Cisplatin Vs. Cetuximab
48. P1-4-7 - Risk Factors of Prolonged Duration of Gastrosoma Placement in Locally Advanced Head and Neck Cancer Patients with Ccrt
49. O1-15-1 - The Pattern of Tumor Shrinkage is Associated with Prognosis in Luminal Breast Cancer During Neoadjuvant Chemotherapy
50. PD1-4 - Molecular Targeting Therapy for Thyroid Cancer: Problems in Clinical Practice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.